Life Lua, Subsidiary of Life Biosciences, Named Fierce Biotech Innovation Award Winner





BOSTON, DECEMBER 13 –Rebecca Willumson, publisher of Fierce Biotech, announced today that Life Lua Technologies Inc., a subsidiary of Life Biosciences Inc., has been named the recipient of the Fierce Innovation Award, Life Sciences Edition, in the Digital Health Solutions Category. Life Lua is a HIPAA-compliant, web- and mobile-access technology platform working to improve patient outcomes by facilitating communication between providers and patients.

“We are thrilled by Fierce Biotech’s recognition of our leading-edge work,” said Michael DeFranco, chief executive officer of Life Lua. “Fierce’s selection of Life Lua for the Innovation Award in the Digital Health Solutions category shows that it recognizes the reality of today’s medical services, where patients and providers are inundated by demands for basic services.” Headquartered in New York City, Life Lua enhances mobile workflows across healthcare organizations.

“Fierce Biotech has recognized the remarkable significance of Lua’s innovative platform,” explained Tristan Edwards, co-founder and chief executive officer of Life Biosciences.  “Direct-to-patient, secure video and messaging allows for the delivery of simple services in an efficient way, like sharing a patient’s results or discussing their known, recurrent issues. That’s real innovation. We couldn’t be more proud and thrilled.”



  • Life Biosciences Overview –

Life Biosciences was co-founded in 2017 by David Sinclair, PhD, AO, a professor in the Department of Genetics at Harvard Medical School, and Tristan Edwards, who developed its innovative structure as Chapter Two in his life, after a highly successful career as a global institutional investor, working across all asset classes.  Life Biosciences is the first and largest company focused on addressing health decline due to aging as a systemic breakdown of the body, rather than a series of isolated events and conditions.

There are six Daughter companies working independently and together within the Life Biosciences research environment. The company provides Daughter companies with the resources required to maximize human potential, including Life Lua’s data and communications platform, experienced management, drug development experience, and a 24,000 square foot, state-of-the-art vivarium, robotics and drug screening facility in Cambridge, Mass (USA), augmented by laboratories and offices on four continents.

#          #          #

Co-founded in 2017 by David Sinclair, PhD, AO, and Tristan Edwards, Life Biosciences is the first and largest company addressing the eight pathways of age-related decline (ARD) as a systemic breakdown of the body, not a series of isolated symptoms and conditions. It has established Daughter companies around the world, led by a Dream Team of respected scientists, to independently and collaboratively attack these pathways through pioneering research and product development. The company provides Daughter companies with the full resources of Life Lua’s data and communications platform; LifeLab, its 24,000- square-foot, state-of-the-art research facility that includes a vivarium, robotics, and drug screening capabilities. Life Biosciences seeks to increase healthspans for everyone, including companion animals.


For more information on Life Biosciences, please visit


Press Contact: